Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 20

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 20
---
 the Proposed Transaction was terminated with no cost to the Company. On December 11, 2024, NewGenIvf announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (“EWIHL”) for a reverse merger, in which EWIHL would, on completion, hold approximately 61.6% of NewGenIvf’s equity (the “EWIHL Proposed Transaction"). The completion of the EWIHL Proposed Transaction is subject to, among other matters, the completion of due diligence, the delivery of draft audited financials for the years ended 2023 and 2024 (the “Draft Financials”) of EWIHL by March 31, 2025, and the negotiation of a definitive agreement. As of the date of this registration statement, EWIHL has not delivered Draft Financials to NewGenIvf and key diligence documents remain pending. As such, the parties have yet to enter into a definitive agreement regarding the EWIHL Proposed Transaction. There can be no assurance that the due diligence will be completed in a manner satisfactory to the Company for entry into definitive agreements, and the Draft Financials will be delivered by March 31, 2025. If the Draft Financials are not delivered by March 31, 2025, NewGenIvf shall exercise its right to terminate the term sheet at no cost to the Company. On February 28, 2025, NewGenIvf completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant to a Purchase Agreement dated January 21, 2025 between NewGenIvf and GIVF (“Purchase Agreement”), NewGenIvf purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort Business (as defined in the Purchase Agreement) from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Class A Ordinary Shares (“MicroSort Acquisition”). White Lion Transaction On November 21, 2024, the Company entered into a Common Shares Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC (“White Lion”) and a related Registration Rights Agreement (the “RRA”). Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to One Hundred Million Dollars ($100,000,